Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data
A Rossi, M Di Maio, P Chiodini, RM Rudd… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Since treatment efficacy of cisplatin-or carboplatin-based chemotherapy in the first-
line treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of …
line treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of …
[HTML][HTML] A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer… - … England Journal of …, 2011 - Mass Medical Soc
Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
[HTML][HTML] Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie… - The Lancet, 2010 - thelancet.com
Background Serum CA125 concentration often rises several months before clinical or
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
[PDF][PDF] High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP …
HC Schouten, W Qian, S Kvaloy… - Journal of clinical …, 2003 - scholar.archive.org
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT)
followed by autologous stem-cell transplantation is more effective than standard treatment …
followed by autologous stem-cell transplantation is more effective than standard treatment …
[HTML][HTML] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a …
D Cunningham, EA Hawkes, A Jack, W Qian, P Smith… - The Lancet, 2013 - thelancet.com
Background Dose intensification with a combination of cyclophosphamide, doxorubicin,
vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older …
vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older …
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
KM Ardeshna, W Qian, P Smith, N Braganca… - The lancet …, 2014 - thelancet.com
Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have
conventionally undergone watchful waiting until disease progression. We assessed whether …
conventionally undergone watchful waiting until disease progression. We assessed whether …
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial
L Lowry, P Smith, W Qian, S Falk, K Benstead… - Radiotherapy and …, 2011 - Elsevier
PURPOSE: This multicentre, prospective, randomised-controlled trial compared efficacy and
toxicity of differing radiotherapy doses in non-Hodgkin lymphoma (NHL). PATIENTS AND …
toxicity of differing radiotherapy doses in non-Hodgkin lymphoma (NHL). PATIENTS AND …
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
SF Barrington, W Qian, EJ Somer… - European journal of …, 2010 - Springer
Purpose To determine if PET reporting criteria for the Response Adapted Treatment in
Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached …
Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached …
[HTML][HTML] Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous …
CA Parkinson, D Gale, AM Piskorz, H Biggs… - PLoS …, 2016 - journals.plos.org
Background Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations
may provide a minimally invasive means to dynamically assess tumour burden and …
may provide a minimally invasive means to dynamically assess tumour burden and …
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic …
GM Mead, SL Barrans, W Qian… - Blood, The Journal …, 2008 - ashpublications.org
This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt
lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified …
lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified …